Keywords: Human Genome Sciences, Novartis, Joueferon, Zabin, Gilead,, GS 9450

Human Genome shares drop as partner Novartis withdraws European MAA for Jouleferon/Zalbin for hep C; and Gilead drops Ph II hep C drug

Article | 20 April 2010

Print This

USA-based Human Genome Sciences saw its shares dip 3% to $31.52 in pre-market trading yesterday, after it announced that its partner, Swiss ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in